Shankar Siva joins the show to discuss the emerging role of stereotactic body radiotherapy (SBRT) in primary and metastatic RCC tumors.

3人による2024年のGU oncoloyのレビューを切れ味鋭く解説しています。乞うご期待！

Tanya Dorff from City of Hope joins Brian and Tom to review what to expect throughout 2025 and beyond in terms of clinically impactful data in prostate, renal and bladder cancer

Silke Gilleson gives Tom and Brian 3 'gifts': Thomas Zilli (Radiation Oncology), Jochen Walz (Urology) and Ken Hermann (Nuclear Medicine) who discuss the 2024 prostate highlights from each of their unique perspectives.

Matt Galsky joins Brian and Tom to discuss the most impactful data in bladder cancer form the past year.

David McDermott (and his dog, Finn) join the show to review the top data from 2024 in RCC

Jim Brugarolas joins to discuss his talk from IKCS 2024 and the board topic of resistance to HIF inhibitors.

JSCO2024で発表されたKEYNOTE-564東アジア人OSデータとANNAR biomarker studyの解説とディスカッションです

Dan Suzman from FDA joins us to discuss the Accelerated Approval process, requirements, successes and challenges.

Jonathan Rosenberg joins Brian and Tom to discuss this important phase 3 trial and efficacy and toxicity signals.